Pyrimidinone fused bicyclic metalloproteinase inhibitors

Details Pyrimidinone fused bicyclic metalloproteinase inhibitors Pyrimidinone fused bicyclic metalloproteinase inhibitors

2003-08-05

2004-12-07

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S259200, C514S259300, C514S259310, C514S259500, C544S263000, C544S255000, C544S278000, C544S281000, C544S282000

Reexamination Certificate

active

06828326

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to fused bicyclic metalloproteinase inhibitors, and to pharmaceutical compositions and methods of treatment of inflammation, cancer and other disorders.
The compounds of the present invention are inhibitors of zinc metalloendopeptidases, especially those belonging to the class of matrix metalloproteinases (also called MMP or matrixin). Matrix metalloproteinases (sometimes referred to as MMPs) are naturally occurring enzymes found in most mammals. Over-expression and activation of MMPs, or an imbalance between MMPs and inhibitors of MMPs, may besuggested as factors in the pathogenesis of diseases characterized by the breakdown of extracellular matrix or connective tissues.
Stromelysin-1 and gelatinase A are members of the MMP family. Other members include fibroblast collagenase (MMP-1), neutrophil collagenase (MMP-8), gelatinase B (92 kDa gelatinase) (MMP-9), stromelysin-2 (MMP-10), stromelysin-3 (MMP-11), matrilysin (MMP-7), collagenase 3 (MMP-13), TNF-alpha converting enzyme (TACE), and other newly discovered membrane-associated matrix metalloproteinases (Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., and Seiki M.,
Nature
, 1994;370:61-65). In total, the MMP subfamily of enzymes, currently contains seventeen members (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20). The MMP's are most well known for their role in regulating the turn-over of extracellular matrix proteins and as such play important roles in normal physiological processes such as reproduction, development and differentiation. In addition, the MMP's are expressed in many pathological situations in which abnormal connective tissue turnover is occurring. For example, MMP-13 an enzyme with potent activity at degrading type II collagen (the principal collagen in cartilage), has been demonstrated to be overexpressed in osteoarthritic cartilage (Mitchell, et al.,
J. Clin. Invest
., 97, 761 (1996)). Other MMPs (MMP-2, MMP-3, MMP-8, MMP-9, MMP-12) are also overexpressed in osteoarthritic cartilage and inhibition of some or all of these MMP's is expected to slow or block the accelerated loss of cartilage typical of joint diseases such as osteoarthritis or rheumatoid arthritis.
These enzymes may beimplicated with a number of diseases which result from breakdown of connective tissue, including such diseases as rheumatoid arthritis, osteoarthritis, osteoporosis, periodontitis, multiple sclerosis, gingivitis, corneal epidermal and gastric ulceration, atherosclerosis, neointimal proliferation which leads to restenosis and ischemic heart failure, and tumor metastasis. A method for preventing and treating these and other diseases is now recognized to be by inhibiting matrix metalloproteinase enzymes, thereby curtailing and/or eliminating the breakdown of connective tissues that results in the disease states. It has also been recognized that different combinations of MMP's are expressed in different pathological situations. As such, inhibitors with specific selectivities for individual MMP's may be preferred for individual diseases.
There is a catalytic zinc domain in matrix metalloproteinases that is typically the focal point for inhibitor design. The modification of substrates by introducing zinc-chelating groups has generated potent inhibitors such as peptide hydroxamates and thiol-containing peptides. Peptide hydroxamates and the natural endogenous inhibitors of MMPs (TIMPS) may beused successfully to treat animal models of cancer and inflammation. MMP inhibitors have also been used to prevent and treat congestive heart failure and other cardiovascular diseases, U.S. Pat. No. 5,948,780.
A major limitation on the use of currently known MMP inhibitors is their lack of specificity for any particular enzyme. Recent data has established that specific MMP enzymes are associated with some diseases, with no effect on others. The MMPs are generally categorized based on their substrate specificity, and indeed the collagenase subfamily of MMP-1, MMP-8, and MMP-13 selectively cleave native interstitial collagens, and thus are associated only with diseases linked to such interstitial collagen tissue. This is evidenced by the recent discovery that MMP-13 alone is over expressed in breast carcinoma, while MMP-1 alone is over expressed in papillary carcinoma (see Chen et al.,
J. Am. Chem. Soc
., 2000;122:9648-9654).
There appears to be few selective inhibitors of MMP-13 reported. A compound named WAY-170523 has been reported by Chen et al., supra., 2000, and a few other compounds are reported in PCT International Application Publication Number WO 01/63244 A1, as allegedly selective inhibitors of MMP-13. Further, U.S. Pat. No. 6,008,243 discloses inhibitors of MMP-13. However, no selective or nonselective inhibitor of MMP-13 has been approved and marketed for the treatment of any disease in any mammal. Accordingly, the need continues to find new low molecular weight compounds that are potent and selective MMP inhibitors, and that have an acceptable therapeutic index of toxicity/potency to make them amenable for use clinically in the prevention and treatment of the associated disease states. An object of this invention is to provide a group of selective MMP-13 inhibitor compounds characterized as fused bicyclics.
Matrix metalloproteinase inhibitors are well known in the literature. Hydroxamic acid MMP inhibitors are exemplified in European Patent Publication 606,046, published Jul. 13, 1994. Several pyrimidine-2,4,6 trione MMP inhibitors are referred to in PCT publication WO 98/58925, published Dec. 30, 1998. PCT publication WO 00/47565, published Aug. 17, 2000 refers to certain aryl substituted fused bicyclic MMP inhibitors. U.S. Non-provisional application Ser. No. 09/635,156, filed Aug. 9, 2000 (which claims priority to U.S. Provisional application No. 60/148,547 filed Aug. 12, 1999) refers to heteroaryl substituted pyrimidine-2,4,6 trione MMP inhibitors. United States Provisional Application entitled “Spiro-Fused bicyclic Metalloproteinase Inhibitors”, filed Oct. 26, 2000, refers to certain 5-spiro pyrimidin-2,4,6-triones. Barbituric acids and methods for their preparation are well known in the art, see for example Goodman and Gilman's, “
The Phamacological Basis of Therapeutics
,” 345-382 (Eighth Edition, McGraw Hill, 1990). Each of the above referenced publications and applications is hereby incorporated by reference in its entirety
SUMMARY OF THE INVENTION
The present invention relates to compounds of the formula:
wherein A is a suitable linker such as
—NR(C═O)—,
—(C═O)NR,
(C
2
-C
6
)alkynyl-,
a bond,
—OC(O)—;
—CH(R)C(O)—;
—OC(NR)—;
—CH(R)C(NR)—;
—N(R)C(O)—;
—N(R)C(S)—;
—N(R)C(NR)—;
—SC(O)—;
—CH(R)C(S)—;
—SC(NR)—;
—C≡CCR
2
—;
—OCH
2
—;
—N(R)CH
2
—;
—C≡C—;
—CR
2
C≡C—;
—CF
2
C≡C—;
—C≡CCF
2
—;
Q is independently C(H) or N; and
T is O, S, N(H), or N(C
1
-C
6
alkyl);
and pharmaceutically acceptable salts thereof;
X is selected from —N═, —NR
9
—, —O—, —S—, —CR
10
, >C(R
11
)
2
,
Y is selected from —N═, —NR
9
—, —O—, —S—, —CR
10
—, >C(R
11
)
2
;
with the proviso that when Y is O or S, X is not O or S;
dashed lines represent optional double bonds;
R, R
1
, R
9
, R
10
, and R
11
are the same or different where ever they appear and each is independently selected from the group consisting of hydrogen, (C
1
-C
6
)alkyl-, (C
2
-C
6
)alkenyl-, (C
2
-C
6
)alkynyl-, (C
3
-C
10
)cycloalkyl-, (C
6
-C
10
)aryl-, (C
1
-C
10
)heterocyclyl-, ((C
1
-C
10
)heteroaryl-, (C
3
-C
10
)cycloalkyl-(C
1
-C
6
)alkyl-, (C
6
-C
10
)aryl-(C
1
-C
6
)alkyl-, (C
1
-C
10
)heterocyclyl-(C
1
-C
6
)alkyl-, (C
1
-C
10
)heteroaryl-(C
1
-C
6
)alkyl-, (C
3
-C
10
)cycloalkyl-(C
2
-C
6
)alkenyl-, (C
6
-C
10
)aryl-(C
2
-C
6
)alkenyl-, (C
1
-C
10
)heterocyclyl-(C
2
-C
6
)alkenyl-, (C
6
-C
10
)aryl-(C
2
-C
6
)alkenyl-, (C
1
-C
10
)heteroaryl-(C
2
-C
6
)alkenyl-, (C
3
-C
10
)cycloalkyl-(C
2
-C
6
)alkynyl-, (C
6
-C
10
)aryl-(C
2
-C
6
)alkynyl

Affiliated with

Also associated with

Rating

Pyrimidinone fused bicyclic metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidinone fused bicyclic metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidinone fused bicyclic metalloproteinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3307111